Phase Ⅰ Study of EGFR Targeted TGFβR-KO CAR T Cells in the Treatment of Previously Treated Advanced EGFR-positive Solid Tumors
Phase Ⅰ Study of EGFR Targeted TGFβR-KO CAR T Cells in the Treatment of Previously Treated Advanced EGFR-positive Solid Tumors is a PHASE1 clinical asset sponsored by Chinese PLA General Hospital in Solid Tumor, Adult, EGFR Overexpression. SEO and diligence focus: TGFβR-KO CAR-EGFR T Cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Solid Tumor, Adult
Modality: protein therapy
Target: TGFβR-KO CAR-EGFR T Cells
Sponsor: Chinese PLA General Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 03, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: TGFβR-KO CAR-EGFR T Cells
View original source fields
Condition raw: Solid Tumor, Adult, EGFR Overexpression
Condition normalized: Solid Tumor, Adult, EGFR Overexpression
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: TGFβR-KO CAR-EGFR T Cells
Target normalized: TGFβR-KO CAR-EGFR T Cells